Tesamorelin
Egrifta · TH9507
An approved analog studied for visceral fat. Still a prescription decision.
A stabilized GHRH analog approved to reduce visceral adipose tissue in HIV lipodystrophy. Used off-label in body-composition research because of a relatively VAT-selective effect.
Usual range
1–2 mg
Schedule
Once daily
Half-life
~26–38 minutes (effect longer via IGF-1)
How it is used
FDA-approved GHRH analog for HIV-associated lipodystrophy.
Subcutaneous
Evening, abdomen subq. Consistent clock time.
Approved trials ran 26–52 weeks. Off-label users often 12–16 weeks.
How to mix this vial
Typical vial 2 mg · 2 mL BAC
Brand kits use a supplied diluent. Compounded 2 mg vials + 2 mL → 1 mg/mL. 1 mg = 100 units.
Follow labeled kit storage. Compounded: fridge after mixing.
Side effects
- Arthralgia
- Edema
- Injection-site reactions
- Glucose elevation
- Paresthesia
Who should skip this
- Active malignancy
- Pregnancy
- Disruption of the hypothalamic-pituitary axis
Nutrition note
Watch fasting glucose. Protein-forward meals; limit late-night refined carbs.
Stacks
Often paired with
Approved molecule (Egrifta) for a specific indication. Compounded copies are not the branded drug.
Peptipedia is an educational calculator, not medical advice. Many catalog entries are unapproved for human use. Approved molecules have labels that outrank this app. Do not use this to self-prescribe. Consult a licensed clinician. Not for anyone under 18, pregnant, or being treated for cancer.